financetom
Business
financetom
/
Business
/
Amalgamated Financial Q3 profit beats expectations on higher interest income 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amalgamated Financial Q3 profit beats expectations on higher interest income 
Oct 23, 2025 4:02 AM

Overview

* Amalgamated Q3 core EPS beats analyst expectations

* Net income for Q3 was $26.8 mln, up from $26.0 mln in prior qtr

* Company repurchased 347,000 shares, totaling $10.4 mln

Outlook

* Company did not provide specific guidance for future quarters

Result Drivers

* NET INTEREST INCOME - Co's net interest income rose by $3.5 mln, driven by higher loan interest income and increased loan yields

* DEPOSIT GROWTH - Political deposits increased by $235 mln, contributing to overall deposit growth

* LOAN GROWTH - Net loans receivable increased by $77 mln, driven by commercial and industrial loan growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Core Beat $0.91 $0.87 (2

EPS Analysts

)

Q3 EPS $0.88

Q3 Core $27.60

Net mln

Income

Q3 Net $26.79

Income mln

Q3 Net $76.44

Interest mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for Amalgamated Financial Corp ( AMAL ) is $31.50, about 15.2% above its October 21 closing price of $26.70

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Abercrombie Q4 Earnings Beat Overshadowed By Cautious Q1 Outlook, Stock Plunges
Abercrombie Q4 Earnings Beat Overshadowed By Cautious Q1 Outlook, Stock Plunges
Mar 5, 2025
Abercrombie & Fitch Company ( ANF ) shares are trading lower in the morning session on Wednesday. The company reported fourth-quarter adjusted earnings per share of $3.57, beating the street view of $3.52. Quarterly sales of $1.585 billion outpaced the analyst consensus estimate of $1.563 billion. The company reported net sales growth of 9%, with comparable sales growth of 14%....
Huron Consulting Grows Philanthropy Focus With Acquisition, Partnership
Huron Consulting Grows Philanthropy Focus With Acquisition, Partnership
Mar 5, 2025
09:57 AM EST, 03/05/2025 (MT Newswires) -- Huron Consulting Group ( HURN ) said Wednesday it has acquired Advancement Resources, a provider of research-based professional education services focused on philanthropy. Financial details weren't disclosed. The company also said it has agreed to collaborate with Halpin Partnership, a UK-based management consultancy specializing in higher education fundraising, governance, and strategy. Shares of...
Sernova Secures $1 Million in Convertible Debt Financing
Sernova Secures $1 Million in Convertible Debt Financing
Mar 5, 2025
09:51 AM EST, 03/05/2025 (MT Newswires) -- Sernova Biotherapeutics (SVA.TO), a regenerative medicine company trading near 52-week lows, on Wednesday announced a $1 million unsecured convertible debenture financing with Dr. Steven Sangha, a Sernova ( SEOVF ) shareholder and board member. The debenture is repayable on March 4, 2027, unless earlier converted or redeemed, and carries a 15% interest rate....
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
Mar 5, 2025
FRANKFURT, March 5 (Reuters) - A German court in Duesseldorf on Wednesday ruled that Pfizer ( PFE ) and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna ( MRNA ). In a statement, the court said that Pfizer ( PFE ) and BioNTech would have to provide information on earnings derived from the use of the patent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved